Excellent to see some solid results for rosacea which pave the way to Ph3 and commercialisation. Rosacea being treatable but largely incurable means ongoing need and a self-sustaining target market, which is much more lucrative than shorter-term dermatitis. Good news. Well done BOT on a great ann. GLTA
Ann: Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea, page-29
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.010(2.82%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.3¢ | 34.5¢ | $582.2K | 1.679M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32454 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 210000 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |